What is this paper about
This paper shows that semaglutide is far more than a weight-loss drug: across a vast evidence base it emerges as a multi-system therapy with meaningful effects on obesity, diabetes, cardiovascular risk, kidney disease, and even liver and neurodegenerative pathways. The full paper is worth reading because it separates the real breadth of benefit from the hype, showing where the evidence is strongest, where safety and access concerns matter, and how semaglutide may be reshaping modern metabolic medicine.
